Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Atherosclerotic cardiovascular disease
Carotid intima-media thickness
Fatty liver index
Liver function tests
Nonalcoholic fatty liver disease
Ursodeoxycholic acid
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 Mar 2021
14 Mar 2021
Historique:
received:
03
12
2020
revised:
30
12
2020
accepted:
24
02
2021
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
15
5
2021
Statut:
ppublish
Résumé
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for treatment of NAFLD, is reported to have a beneficial effect on dyslipidemia and ASCVD risk because of antioxidant properties. To evaluate the effects of 6 mo of UDCA treatment on hepatic function tests, lipid profile, hepatic steatosis and fibrosis, atherogenesis, and ASCVD risk in men and women with NAFLD, as well as to assess the impact of > 5% weight reduction on these parameters. An open-label, multicenter, international noncomparative trial was carried out at primary health care settings and included 174 patients with ultrasound-diagnosed NAFLD who received 15 mg/kg/d UDCA for 6 mo and were prescribed lifestyle modification with diet and exercise. The efficacy criteria were liver enzymes, lipid profile, fatty liver index (FLI), noninvasive liver fibrosis tests (nonalcoholic fatty liver disease fibrosis score and liver fibrosis index), carotid intima-media thickness (CIMT), and ASCVD risk score. To test statistical hypotheses, the Wilcoxon test, paired The alanine aminotransferase (ALT) level changed by -14.1 U/L (-31.0; -5.3) from baseline to 3 mo and by -6.5 U/L (-14.0; 0.1) from 3 to 6 mo. The magnitude of ALT, aspartate transaminase, and glutamyltransferase decrease was greater during the first 3 mo of treatment compared to the subsequent 3 mo ( UDCA normalizes liver enzymes greatly within the first 3 mo of treatment, improves lipid profile and hepatic steatosis independent of weight loss, and has a positive effect on CIMT in the total sample and 10-year ASCVD risk in women after 6 mo of treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for treatment of NAFLD, is reported to have a beneficial effect on dyslipidemia and ASCVD risk because of antioxidant properties.
AIM
OBJECTIVE
To evaluate the effects of 6 mo of UDCA treatment on hepatic function tests, lipid profile, hepatic steatosis and fibrosis, atherogenesis, and ASCVD risk in men and women with NAFLD, as well as to assess the impact of > 5% weight reduction on these parameters.
METHODS
METHODS
An open-label, multicenter, international noncomparative trial was carried out at primary health care settings and included 174 patients with ultrasound-diagnosed NAFLD who received 15 mg/kg/d UDCA for 6 mo and were prescribed lifestyle modification with diet and exercise. The efficacy criteria were liver enzymes, lipid profile, fatty liver index (FLI), noninvasive liver fibrosis tests (nonalcoholic fatty liver disease fibrosis score and liver fibrosis index), carotid intima-media thickness (CIMT), and ASCVD risk score. To test statistical hypotheses, the Wilcoxon test, paired
RESULTS
RESULTS
The alanine aminotransferase (ALT) level changed by -14.1 U/L (-31.0; -5.3) from baseline to 3 mo and by -6.5 U/L (-14.0; 0.1) from 3 to 6 mo. The magnitude of ALT, aspartate transaminase, and glutamyltransferase decrease was greater during the first 3 mo of treatment compared to the subsequent 3 mo (
CONCLUSION
CONCLUSIONS
UDCA normalizes liver enzymes greatly within the first 3 mo of treatment, improves lipid profile and hepatic steatosis independent of weight loss, and has a positive effect on CIMT in the total sample and 10-year ASCVD risk in women after 6 mo of treatment.
Identifiants
pubmed: 33776366
doi: 10.3748/wjg.v27.i10.959
pmc: PMC7968130
doi:
Substances chimiques
Ursodeoxycholic Acid
724L30Y2QR
Types de publication
Clinical Trial
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
959-975Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Maria Yu. Nadinskaia, in 2015-2019 provided consulting services for the PRO.MED.CS Marketing. Marina V. Maevskaya in 2015-2019 provided consulting services for the PRO.MED.CS Marketing. Vladimir T. Ivashkin in 2015-2019, provided consulting services for the PRO.MED.CS Marketing. Feruza I. Khamrabaeva in 2015-2019, provided consulting services for the PROMEDCSCA. Elena B. Zueva, in 2015-2019, provided consulting services for the PROMEDCSCA. Alexander V. Nersesov, in 2018-2019, provided consulting services for the PROMEDCSCA. Aigul M. Raissova, in 2018-2019, provided consulting services for the PROMEDCSCA. Khava B. Kodzoeva declares that there are no conflicts of interest. Irina Yu. Pirogova declares that there are no conflicts of interest. Evgenii V. Chesnokov declares that there are no conflicts of interest. Jamilya A. Kaibullayeva declares that there are no conflicts of interest. Akzhan Konysbekova declares that there are no conflicts of interest.
Références
Crit Pathw Cardiol. 2005 Dec;4(4):198-203
pubmed: 18340209
J Hepatol. 2016 Sep;65(3):589-600
pubmed: 27212244
Acta Diabetol. 2013 Apr;50(2):241-9
pubmed: 22684314
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
Eur Heart J. 2013 Aug;34(30):2368-80
pubmed: 23186808
Hepatology. 1996 Jun;23(6):1464-7
pubmed: 8675165
Pharmacology. 2002 May;65(1):2-9
pubmed: 11901295
J Gastroenterol Hepatol. 2013 Oct;28(10):1654-9
pubmed: 23731053
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023
pubmed: 24239920
Hepatology. 2010 Feb;51(2):595-602
pubmed: 20014114
J Hepatol. 2018 May;68(5):1018-1024
pubmed: 29274406
Am J Transplant. 2020 Jan;20 Suppl s1:193-299
pubmed: 31898413
J Gastroenterol Hepatol. 2002 Feb;17(2):196-202
pubmed: 11966951
High Blood Press Cardiovasc Prev. 2020 Aug;27(4):321-330
pubmed: 32436128
Eur J Gastroenterol Hepatol. 2015 Feb;27(2):142-9
pubmed: 25533429
J Gastroenterol. 2012 May;47(5):586-95
pubmed: 22328022
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S209-S216
pubmed: 28017631
Pediatr Res. 1994 Feb;35(2):214-7
pubmed: 8165057
J Hepatol. 2011 May;54(5):1011-9
pubmed: 21145828
Chin Med J (Engl). 2009 Dec 5;122(23):2827-32
pubmed: 20092785
Circ J. 2012;76(8):2041-7
pubmed: 22664416
Hepatol Res. 2016 Aug;46(9):862-70
pubmed: 26763834
J Hepatol. 2016 Jul;65(1):95-102
pubmed: 27129836
Front Pharmacol. 2020 Oct 16;11:594496
pubmed: 33178028
J Hepatol. 2015 Jan;62(1):182-9
pubmed: 25195550
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Hepatol. 2013 Sep;59(3):536-42
pubmed: 23623998
J Hepatol. 2015 Jun;62(6):1398-404
pubmed: 25617503
Blood Press. 2017 Feb;26(1):48-53
pubmed: 27216375
Gut. 1996 Sep;39(3):475-8
pubmed: 8949657
Med Clin (Barc). 2013 Sep 21;141(6):233-9
pubmed: 23601740
Biochem Pharmacol. 2002 Dec 1;64(11):1661-7
pubmed: 12429355
Hepatology. 2010 Jul;52(1):79-104
pubmed: 20578268
Hepatology. 2002 Apr;35(4):779-89
pubmed: 11915023
Clin Liver Dis. 2004 Feb;8(1):67-81, vi
pubmed: 15062194
Cardiovasc Diabetol. 2016 Jan 22;15:13
pubmed: 26801098
Am Heart J. 2018 Jun;200:83-89
pubmed: 29898853
PLoS One. 2014 Nov 06;9(11):e111808
pubmed: 25375228
Nat Rev Gastroenterol Hepatol. 2012 May 08;9(7):372-81
pubmed: 22565095
Eur J Intern Med. 2014 Oct;25(8):762-7
pubmed: 25262992
PLoS One. 2016 Jul 15;11(7):e0158710
pubmed: 27420035
Can J Gastroenterol. 2003 Dec;17(12):713-8
pubmed: 14679419
Lipids Health Dis. 2019 Apr 6;18(1):88
pubmed: 30954082
Adv Ther. 2017 Jun;34(6):1291-1326
pubmed: 28526997
Diabet Med. 2018 Mar;35(3):368-375
pubmed: 29247558
Clin Gastroenterol Hepatol. 2006 Dec;4(12):1537-43
pubmed: 17162245
Endocr Rev. 2020 Jan 1;41(1):
pubmed: 31629366
Diabetes Care. 2017 Jun;40(6):808
pubmed: 28420697
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
JAMA Intern Med. 2019 Jul 1;:
pubmed: 31260026
Adv Med Sci. 2006;51:54-9
pubmed: 17357278
J Hepatol. 2015 Jul;63(1):237-64
pubmed: 25911335
Oncol Rep. 2012 Oct;28(4):1429-34
pubmed: 22824956
Eur Heart J Cardiovasc Pharmacother. 2017 Apr 1;3(2):82-89
pubmed: 27533954
J Prim Care Community Health. 2018 Jan-Dec;9:2150132718773674
pubmed: 29756523
Biochem Pharmacol. 2009 Mar 1;77(5):858-66
pubmed: 19073151
J Am Coll Cardiol. 2017 Mar 28;69(12):1617-1636
pubmed: 27825770
Saudi J Gastroenterol. 2016 May-Jun;22(3):192-7
pubmed: 27184636
Hepatology. 2010 Aug;52(2):472-9
pubmed: 20683947
Hepatology. 2004 Mar;39(3):770-8
pubmed: 14999696
Am J Gastroenterol. 2001 May;96(5):1558-62
pubmed: 11374699